ReviewJournal of clinical medicine2024
Vitiligo: From Pathogenesis to Treatment.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of Simvastatin in the treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials.Archives of dermatological research · 2025Pooled it
- Mechanistic Insights into Phytocompounds for Vitiligo Therapy: Current Evidence and Future Opportunities.Antioxidants (Basel, Switzerland) · 2026Review
- Association of Serum Interleukin-17 Levels With Vitiligo: A Pilot Cross-Sectional Comparative Study.Cureus · 2026Article
- The possible therapeutic effect of platelet-rich plasma versus its derived exosomes in a hydrogen peroxide-induced depigmentation model in adult guinea pigs: a histological study.Journal of molecular histology · 2026Article
- Relationship between dietary inflammation index and progression of vitiligo.Nutrition journal · 2026Article
- IL-21 rs2055979 and serum IL-21 levels are associated with both non-segmental and segmental vitiligo in an Iranian cohort.BMC immunology · 2026Article
- Vitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation.Clinical reviews in allergy & immunology · 2026Review
- Review
- Sympathetic nerve aggravates autoimmune skin disease via NE-adrenergic receptor axis: Neuroimmune cross-talk insights from vitiligo.Science advances · 2026Article
- Epigenetic Therapies for Inflammatory and Immune-Mediated Skin Diseases.Biomedicines · 2026Review
- MSC-Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges-A Narrative Review.International journal of dermatology · 2026Review
- Multimodal Masked Autoencoder Based on Adaptive Masking for Vitiligo Stage Classification.Journal of imaging informatics in medicine · 2026Article
- Minimally invasive 1 mm skin biopsies capture site-specific transcriptomic heterogeneity in vitiligo.Frontiers in immunology · 2026Article
- Mast cells: "central regulatory hub" of neuro-endocrine-immune dysregulation in vitiligo.Frontiers in immunology · 2026Review
- Oral Ivarmacitinib for Stable Vitiligo: Preliminary Observations from a Three-Patient Case Series.Clinical, cosmetic and investigational dermatology · 2026Article
- From Mechanisms to Clinical Practice: Advances in Vitiligo Treatment Across Western Medicine and Traditional Chinese Medicine.Clinical, cosmetic and investigational dermatology · 2026Review
- Gut and skin microbiome-metabolome pathways in vitiligo: from dysbiosis to immune activation and melanocyte dysfunction.Frontiers in immunology · 2026Review
- Platelet-rich therapies in cutaneous and mucocutaneous disorders characterized by inflammatory tissue responses: mechanistic insights and clinical evidence.Frontiers in medicine · 2026Review
- Development and Validation of an HPLC-MS/MS Method for Pharmacokinetic Evaluation of Tofacitinib/Simvastatin Compound Ointment in Rats.Drug design, development and therapy · 2026Article
- Emerging cell-based and cell-free therapeutic strategies for vitiligo.Journal of translational autoimmunity · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in vitiligo have provided promising treatment options, particularly through understanding the immune-mediated mechanisms leading to depigmentation. The inflammatory components in both vitiligo (non-segmental) and segmental vitiligo have similarities. Both are believed to result from an immune-based destruction of melanocytes by anti-melanocyte-specific cytotoxic T cells. The JAK-STAT pathway is activated with IFN-γ as the crucial cytokine and Th1-associated chemokines such as CXCL9 and CXCL10 recruit immune cells towards vitiligo skin. Nonetheless, clear differences are also present, such as the localized nature of segmental vitiligo, likely due to somatic mosaicism and increased presence of poliosis. The differing prevalence of poliosis suggests that the follicular immune privilege, which is known to involve immune checkpoints, may be more important in vitiligo (non-segmental). Immunomodulatory therapies, especially those targeting the JAK-IFNγ pathway, are currently at the forefront, offering effective inhibition of melanocyte destruction by cytotoxic T cells. Although Janus Kinase (JAK) inhibitors demonstrate high repigmentation rates, optimal results can take several months to years. The influence of environmental UV exposure on repigmentation in patients receiving immunomodulating drugs remains largely underexplored. Nonetheless, the combined effect of phototherapy with JAK inhibitors is impressive and suggests a targeted immune-based treatment may still require additional stimulation of melanocytes for repigmentation. Identifying alternative melanocyte stimulants beyond UV light remains crucial for the future management of vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.